nach oben

Erschienen in:

01.03.2017 | case report

Botulinum toxin A and/or soft tissue fillers for facial rehabilitation

verfasst von: Prof. Dr. Uwe Wollina, Alberto Goldman

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 3-4/2017

Einloggen, um Zugang zu erhalten

Summary

Botulinum toxin A and soft tissue fillers are cornerstones of facial rejuvenation procedures. They can also be of benefit in facial rehabilitation. We report on three female patients who were treated with botulinum toxin A and/or hyaluronic acid-based fillers, one after orthognathic surgery, two after Bell’s palsy, to correct facial asymmetries and loss of volume to restore facial attractiveness and improve their self-esteem and quality of life. These minimally invasive procedures are safe and effective. However, they need to be repeated for the long-term rehabilitation.

Vorheriger Artikel ASIA – a dangerous beauty?

Wollina U. Botulinum toxin: Mechanism of action and possible non-cosmetic indications. J Cutan Aesthet Surg. 2008;1:1–4.

Wollina U, Goldman A. Hyaluronic acid dermal fillers: Safety and efficacy for the treatment of wrinkels, aging skin, body sculpturing and medical conditions. Clin Med Rev Therapeutics. 2011;3:107–21.CrossRef

Mohamed WV, Perenack JD. Aesthetic adjuncts with orthognathic surgery. Oral Maxillofac Surg Clin North Am. 2014;26:573–85.CrossRefPubMed

Wollina U. Perioral rejuvenation: restoration of attractiveness in aging females by minimally invasive procedures. Clin Interv Aging. 2013;8:1149–55.CrossRefPubMedPubMedCentral

Schweiger ES, Riddle CC, Tonkovic-Capin V, Aires DJ. Successful treatment with injected hyaluronic acid in a patient with lip asymmetry after surgical correction of cleft lip. Dermatol Surg. 2008;34:717–9.PubMed

Peitersen E. Bell’s palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol. 2002;122:4–30.CrossRef

Holland J. Bell’s palsy. BMJ Clin Evid. 2008;2008:1204.PubMedPubMedCentral

Beurskens CHG, Oosterhof J, Nijhuis-van der Sanden MWG. Frequency and location of synkinesis in patients with peripheral facial nerve paresis. Otol Neurotol. 2010;31:671–5.PubMed

Azuma T, Nakamura K, Takahashi M, et al. Mirror biofeedback rehabilitation after administration of single-dose botulinum toxin for treatment of facial synkinesis. Otolaryngol Head Neck Surg. 2012;146:40–5.CrossRefPubMed

10.

Wiener A, Touloei K, Glick BP. A novel long-term therapy of facial synkinesis with botulinum neurotoxins type A and fillers. J Clin Aesthet Dermatol. 2011;4:45–9.PubMedPubMedCentral

11.

Choi KI, Rho SH, Lee JM, Jeon JH, Park SY, Kim J. Botulinum toxin injection of both sides of the face to treat post-paralytic facial synkinesis. J Plast Reconstr Aesthet Surg. 2013;66:1058–63.CrossRefPubMed

12.

Pourmomeny AA, Asadi S, Cheatsaz A. Management of facial synkinesis with a combination of BTX-A and biofeedback: a randomized trial. Iran J Otorhinolaryngol. 2015;27:409–15.PubMedPubMedCentral

13.

Kopera D, Palatin M, Bartsch R, Bartsch K, O’Rourke M, Höller S, Baumgartner RR, Prinz M. An open-label uncontrolled, multicenter study for the evaluation of the efficacy and safety of the dermal filler Princess VOLUME in the treatment of nasolabial folds. Biomed Res Int. 2015;2015:195328.CrossRefPubMedPubMedCentral

Titel: Botulinum toxin A and/or soft tissue fillers for facial rehabilitation
verfasst von: Prof. Dr. Uwe Wollina
Alberto Goldman
Publikationsdatum: 01.03.2017
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 3-4/2017
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-016-0512-8

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3-4/2017

Global dermatology: challenges and changes?

Trombiculiasis: not only a matter of animals!

ASIA – a dangerous beauty?

Terra firma-forme dermatosis

Disseminated superficial actinic porokeratosis (DSAP): significant improvement after local administration of calcipotriol/betamethasone gel?

Pyoderma gangrenosum—a novel approach?